Data on Inspire's glaucoma program has been presented at various medical meetings and published in peer-reviewed publications
2010
Ritch R, Schiewe M, Zink RC, Lemp M, Kaufman PL, Haque R, Brazzell RK, Vittitow
JL. Latrunculin B (INS115644) reduces intraocular pressure (IOP) in ocular
hypertension (OHT) and primary open angle glaucoma (POAG). Poster presented
at the Association for Research in Vision & Ophthalmology (ARVO) 2010
Annual Meeting. 2010 May 2-6; Fort Lauderdale, Florida, USA Poster
in PDF
2008
Peterson WM, Lampe J, Navratil T, Paran Y, Kam Z, Hennes EA, Gabelt BT, Geiger
B, Kaufman PL, Vittitow JL. Topical administration of a novel and potent
rho kinase (ROK) inhibitor INS117548 alters the actin cytoskeleton, effectively
lowers IOP, and is well tolerated on the ocular surface. Poster presented
at the ARVO (Association for Research in Vision & Ophthalmology) 2008
Annual Meeting. 2008 Apr 27 - May 1; Fort Lauderdale, Florida, USA. Poster
in PDF
Verhoeven RS, Kuney N, Robinson C, Peterson WM, Vittitow JL. Topical administration of cytoskeletal disrupting agents modulates central corneal thickness, pupil diameter and pupillary light response in the New Zealand white rabbit. Poster presented at the ARVO (Association for Research in Vision & Ophthalmology) 2008 Annual Meeting. 2008 Apr 27 - May 1; Fort Lauderdale, Florida, USA. Poster in PDF
2007
Watson PS, She J, Lampe JW, Polianski AB. The total systhesis of latrunculin B. Poster presented at The Gordon Research Conference on Natural Products. 2007 July 22-27; Tilton, New Hampsire, USA.
2004
Okka, Tian and Kaufman. Trans Am Ophthalmol Soc. 2004; 102 :251-7.
Denufosol tetrasodium inhalation solution for cystic fibrosis - Phase 3
(diquafosol tetrasodium ophthalmic solution) 2% for dry eye - Phase 3; Approvable
(azithromycin ophthalmic solution) 1% for blepharitis - Phase 2
INS115644 and INS117548 for glaucoma - Phase 1
© Inspire Pharmaceuticals 2010 All Rights Reserved
Terms of Use Legal Notices
Page Updated on: 7/9/2010
